Drug Trial Radar · NCT06505928
A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Dec 11, 2024
Primary completion
May 1, 2026
Study completion Jul 9, 2026
Sponsor
- Lead sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. Patients with compensated CHD who satisfy the eligibility criteria are stratified by the presence or absence of liver cirrhosis and randomized into three groups at a 1:1:1 ratio. The subjects will receive continuous L47 (2.1 mg/d and 4.2 mg/d, s.c.) treatment for 48 weeks (groups A and B), or delayed treatment for 48 weeks (group C). Primary endpoint evaluation will be performed after the subjects complete the 48-week treatment.
Conditions
- Hepatitis D
Interventions
hepalatideDrug
hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- compound responseTime frame: Week 48
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
National cancer canter of Monglia
Ulaanbaatar, Mongolia
National Center for Communicable Diseases
Ulaanbaatar, Mongolia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.